21 December 2016
Smith & Nephew, (LSE:SN, NYSE:SNN), the global medical technology business, has been awarded the 2016 French Galien Award for PICO; the novel single-use negative pressure wound therapy (NPWT) system.
Left to right: Ms Victorine Carré, President of the Jury of the Galien Award ; Pierre Logé, Health Economics and Market Access Manager, Smith & Nephew SAS ; Chantal Gendrey, Business Unit Director Wounds Management, Smith & Nephew SAS ; Bertrand L’Huillier, President of Smith & Nephew SAS
The Prix Galien acknowledges significant advances in pharmaceuticals and medical devices which deliver real improvements to human life. The prize, awarded in the Medical Disability Compensation and Return to Social Life category, rewards Smith & Nephew’s determination to improve the daily lives of patients and professionals with the management of wounds.
Managing Director of Smith & Nephew SAS (France), Bertrand L'Huillier, said: "Receiving the Galien Award is a huge honour and recognition of our contribution to medical research and ability to innovate. It is also a great encouragement to continue our investment to support healthcare professionals in their daily efforts to improve the lives of patients worldwide."
Improving community healthcare and patient outcomes
Managing wounds, whether chronic, acute or post-surgical, has a significant impact to a patients’ quality of life as well as a financial impact on the health economy[i]. Chronic wounds are often hard to heal, resulting in a cycle of pain, anxiety, frequent home visits and reduced quality of life. However, with the availability of the PICO system in the community, the lives of patients with wounds are significantly improved[i].
A study of 326 community based patients whom received PICO treatment for pressure ulcers, leg ulcers, diabetic foot ulcers, trauma wounds and dehisced surgical wounds, showed that prior to using PICO wound dressings were being changed four times a week[ii]. This fell to two dressing changes a week when using PICO, and to 1.8 times a week, on average, in the four-week follow-up period. Fewer dressing changes resulted in considerable cost savings; the total cost of care using PICO was three times less than the baseline[iii].
PICO is a novel, canister-free single use system that offers portable, accessible and affordable NPWT, overcoming many of the disadvantages of conventional NPWT devices. PICO’s unique dressing technology not only absorbs and locks exudate but is designed to move exudate away from the wound and aids evaporation of fluidiv. The PICO pump maintains negative pressure at -80mmHg through the wound bed and dressing[iv]. The PICO system can be used up to 7 days depending on levels of exudate, and includes two dressings.
PICO is cleared for use in hospital and homecare settings in Europe, US, Canada, and Australia. In Japan PICO is cleared for use in open wounds only. For more information about the PICO system and the NPWT portfolio of products from Smith & Nephew, please visit www.smith-nephew.com. Clinicians and patients may also refer to the 24/7 Negative Pressure Wound Therapy hotline, 0800 9155394 (UK) and 1800 303 622 (Ireland).
About the Prix Galien
Each year, the Prix Galien rewards therapeutic innovations made available to healthcare professionals and patients as well as pharmaceutical research. The honor committee includes the most prominent figures in the scientific world, including several Nobel Prize winners. The Prix Galien is regarded as the highest distinction awarded each year to pharmaceutical research.
Recognition at the French Galien Awards means that Smith & Nephew will now be able to enter PICO into the international Galien Awards, held in 2018.
A full press pack, containing clinical and product imagery, videos, and background information is available on this page.
Beth Lowes or Rachel Cunningham
0208 995 5832
ROAD Communications on behalf of
About Smith & Nephew
Smith & Nephew is a global medical technology business dedicated to helping healthcare professionals improve people's lives. With leadership positions in Orthopaedic Reconstruction, Advanced Wound Management, Sports Medicine and Trauma & Extremities, Smith & Nephew has around 15,000 employees and a presence in more than 100 countries. Annual sales in 2015 were more than $4.6 billion. Smith & Nephew is a member of the FTSE100 (LSE:SN, NYSE:SNN).
For more information about Smith & Nephew, please visit our website www.smith-nephew.com, follow @SmithNephewplc on Twitter or visit SmithNephewplc on Facebook.com.
To learn more about what we do to help reduce surgical site complications, please visit www.closertozero.com
This document may contain forward-looking statements that may or may not prove accurate. For example, statements regarding expected revenue growth and trading margins, market trends and our product pipeline are forward-looking statements. Phrases such as "aim", "plan", "intend", "anticipate", "well-placed", "believe", "estimate", "expect", "target", "consider" and similar expressions are generally intended to identify forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other important factors that could cause actual results to differ materially from what is expressed or implied by the statements. For Smith & Nephew, these factors include: economic and financial conditions in the markets we serve, especially those affecting health care providers, payers and customers; price levels for established and innovative medical devices; developments in medical technology; regulatory approvals, reimbursement decisions or other government actions; product defects or recalls or other problems with quality management systems or failure to comply with related regulations; litigation relating to patent or other claims; legal compliance risks and related investigative, remedial or enforcement actions; disruption to our supply chain or operations or those of our suppliers; competition for qualified personnel; strategic actions, including acquisitions and dispositions, our success in performing due diligence, valuing and integrating acquired businesses; disruption that may result from transactions or other changes we make in our business plans or organisation to adapt to market developments; and numerous other matters that affect us or our markets, including those of a political, economic, business, competitive or reputational nature. Please refer to the documents that Smith & Nephew has filed with the U.S. Securities and Exchange Commission under the U.S. Securities Exchange Act of 1934, as amended, including Smith & Nephew's most recent annual report on Form 20-F, for a discussion of certain of these factors. Any forward-looking statement is based on information available to Smith & Nephew as of the date of the statement. All written or oral forward-looking statements attributable to Smith & Nephew are qualified by this caution. Smith & Nephew does not undertake any obligation to update or revise any forward-looking statement to reflect any change in circumstances or in Smith & Nephew's expectations.
◊Trademark of Smith & Nephew.
[i] Reducing the burden of chronic wounds in the community with single-use NPWT’ JCN supplement 2015, Vol 29, No 5
[ii] Hurd et al., Use of a portable, single-use negative pressure wound therapy device in home care patients with low to moderately exuding wounds: A case series. Ostomy Wound Management, March 2014.
[iii] Hampton J, Providing cost-effective treatment of hard-to-heal wounds in the community through use of NPWT. British Journal of Community Nursing, Vol 20, No 6, Community Wound Care, June 2015.
[iv] Malmsjö M, Huddleston E, Martin R. Biological effects of a disposable, canisterless negative pressure wound therapy system. Eplasty 2014;14:e15.